A self-assembled albumin based multiple drug delivery nanosystem to overcome multidrug resistance
RSC Advances, ISSN: 2046-2069, Vol: 5, Issue: 9, Page: 6807-6814
2015
- 19Citations
- 20Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
A facile strategy to construct a multiple drug delivery platform to overcome multidrug resistance (MDR) was developed. A nano-sized albumin based drug delivery system with the capability to simultaneously entrap different drugs was prepared by self-assembly. An anti-tumor drug (doxorubicin, DOX) and a drug resistance inhibitor (verapamil, VER) were efficiently co-loaded in bovine serum albumin (BSA) to obtain DOX/VER/BSA nanoparticles. The interactions between the drugs (DOX and VER) and BSA were studied by fluorescence spectroscopy. The size and zeta potential of the nanoparticles were determined by dynamic light scattering (DLS). The morphology of the nanoparticles was observed by transmission electron microscopy (TEM). DOX/VER/BSA nanoparticles exhibited a spherical shape with a mean size around 50 nm. The in vitro tumor cell inhibition efficiency of the nanoparticles was evaluated in HCT-15 cells with a moderate overexpression of P-glycoprotein (P-gp) as compared with 293T cells without overexpression of of P-gp. As compared with free DOX and DOX/BSA nanoparticles, DOX/VER/BSA nanoparticles exhibited a stronger tumor cell inhibitory effect because of the enhanced intracellular DOX concentration caused by the efflux pump inhibition of VER. These results indicated that the BSA based multiple drug delivery platform could be promising for drug delivery for overcoming multidrug resistance in cancer treatments.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84920806069&origin=inward; http://dx.doi.org/10.1039/c4ra12802h; https://xlink.rsc.org/?DOI=C4RA12802H; http://xlink.rsc.org/?DOI=C4RA12802H; http://pubs.rsc.org/en/content/articlepdf/2015/RA/C4RA12802H; https://dx.doi.org/10.1039/c4ra12802h; https://pubs.rsc.org/en/content/articlelanding/2015/ra/c4ra12802h
Royal Society of Chemistry (RSC)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know